Search for topics, articles, videos, research, etc...
Hit enter to search or ESC to close
Are you looking for:
MJFF Publications
Donate
Access Resources

MJFF Publications

The Michael J. Fox Foundation continually strives to communicate our scientific progress with the research community — through posters and presentations at meetings, in peer-reviewed scientific publications and with white paper reports.

 From
To
  • Default content image

    Overview of Parkin Models

    Mutations in the parkin gene cause autosomal recessive, young onset Parkinson’s disease (PD). The PD-linked mutations in parkin lead to loss of expression/function of the Parkin protein, an E3…
    Learn more
  • Default content image

    Overview of PINK1 Models

    Mutations in the PTEN-induced kinase 1 (PINK1)  gene cause autosomal recessive, young onset Parkinson’s disease (PD). The PD-linked mutations in PINK1 lead to loss of expression/function of the PINK1…
    Learn more
  • Default content image

    Overview of Mitochondrial Dysfunction Models

    Mitochondrial function is a pathway of great interest for Parkinson’s disease (PD) research and therapeutic development given the dysfunction that has been observed in idiopathic patients, patients…
    Learn more
  • Default content image

    Overview of Inflammation Models

    Inflammation is a pathway of great interest for Parkinson’s disease (PD) research and therapeutic development given evidence of innate and adaptive immune changes in PD patients. Inflammation is also…
    Learn more
  • Default content image

    Overview of GBA1 Models

    The most common genetic form of Parkinson’s disease (PD) is caused by heterozygous mutations in the GBA1 gene which encodes the lysosomal enzyme GCase, leading to decreased activity and accumulation…
    Learn more
  • Default content image

    Overview of LRRK2 Models

    The mutations in the LRRK2 gene which increase the LRRK2 kinase activity are a common genetic form of Parkinson’s disease (PD). The most common mutation is the G2019S mutation which increases kinase…
    Learn more
  • Default content image

    Overview of Alpha-Synuclein Models

    As one of the hallmarks of Parkinson’s disease, alpha-synuclein (aSyn) pathology is a highly desired readout in model systems. There are many in vivo models available that use aSyn mutations,…
    Learn more

Articles authored by Rachel Dolhun, MD, a movement disorder specialist on staff at MJFF, offer a practical review of topics related to Parkinson's disease for practicing clinicians.

 From
To

No results were found.

Michael J. Fox Foundation publications supported through our OAP program.

We believe that the results of all MJFF-funded research should be promptly published and broadly disseminated to accelerate innovation and foster collaboration toward our shared goal of new treatments and cures for Parkinson’s disease. 

Request open access coverage funds for your MJFF project here

 From
To
  • Default content image

    Beta2-Adrenoreceptor Agonist Clenbuterol Produces Transient Decreases in Alpha-Synuclein mRNA but No Long-term Reduction in Protein

    β2-adrenoreceptor (β2AR) agonists have been associated with a decreased risk of developing Parkinson's disease (PD) and are hypothesized to decrease expression of both alpha-synuclein mRNA (Snca) and…
    Learn more
  • Default content image

    Analysis of hemisphere-dependent effects of unilateral intrastriatal injection of α-synuclein pre-formed fibrils on mitochondrial protein levels, dynamics, and function

    Genetic and neuropathological evidence strongly implicates aberrant forms of α-synuclein in neurodegeneration. Antibodies specific for α-synuclein phosphorylated at serine 129 (pS129) are selective…
    Learn more
  • Default content image

    Lipid pathway dysfunction is prevalent in patients with Parkinson's disease

    Many genetic risk factors for Parkinson's disease have lipid-related functions and lipid-modulating drugs such as statins may be protective against Parkinson's disease. Moreover, the hallmark…
    Learn more
  • Default content image

    The GBA1 D409V mutation exacerbates synuclein pathology to differing extents in two alpha-synuclein models

    Abstract Heterozygous mutations in the GBA1 gene-encoding lysosomal glucocerebrosidase (GCase)--are the most common genetic risk factor for Parkinson's disease (PD). Experimental evidence suggests a…
    Learn more
  • Default content image

    Association of Motor and Nonmotor Symptoms With Health-Related Quality of Life in a Large Online Cohort of People With Parkinson Disease

    Abstract Background: There is growing interest in health-related quality of life (HRQOL) as a comprehensive view of the patient's well-being, guiding concept for the treating clinician, and…
    Learn more
  • Default content image

    Design of the PERSPECTIVE study: PERsonalized SPEeCh Therapy for actIVE conversation in Parkinson's disease (randomized controlled trial)

    Objective: To evaluate the effectiveness of personalized and home-based speech therapy on quality of life, intelligibility, and social participation for people with Parkinson's disease (PD) who have…
    Learn more
  • Default content image

    Effect of LRRK2 protein and activity on stimulated cytokines in human monocytes and macrophages

    Abstract Leucine-rich-repeat kinase 2 (LRRK2), a potential therapeutic target for the treatment of Parkinson's disease (PD), is highly expressed in monocytes and macrophages and may play a role in…
    Learn more
Female researcher pipetting in lab.

Breaking Research Updates

Read the latest developments in the field’s understanding and treatment of Parkinson’s disease.

Read Research News
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.
Here. Until Parkinson's isn't.
Join us as we work to find a cure for the 6 million people worldwide living with Parkinson's.
 
 
 
 
Month
Day
Year